Encorafenib plus cetuximab for treatment of BRAFV600E-mutant metastatic colorectal cancer: A case study

Dr Ka On Lam, a specialist in Clinical Oncology in Hong Kong, discusses the current treatment landscape of BRAFV600E-mutant metastatic colorectal cancer (mCRC) and addresses the management challenges associated with patients treated with encorafenib plus cetuximab.